glp-1 obesity drug news today september 15 2025 New Daily Weight Loss Pill Aims to Take on Ozempic New GLP-1 Pill Foundayo (Orforglipron)

Semaglutide withdrawal symptoms extend beyond simple weight regain, with many patients reporting a return of intense food cravings and appetite increases that feel overwhelming after months of suppressed hunger

Wilding, JPH, Batterham, RL, Calanna, S, et al

Its a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results

As noted in most testimonials, its true that the majority of patients experience some side effects to varying degrees

Diabetologia 56, 14131416

Meaningful body-weight reductions , though slightly less than in non-diabetic participants a trend also seen with injectable GLP-1 receptor agonists These results show why orforglipron is being closely monitored as a potential long-term oral GLP-1 medication for weight management and metabolic health